Zoi E. Sychev

Zoi E. Sychev

Auto-generated profile, based on publicly available information

Zoi E. Sychev

Department of Pharmacology, University of Minnesota, Minneapolis, Minnesota

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2024 in Molecular Cancer Research
Verified
Journal Article
Open access
PDF file
ZSZoi E. Sychev
Zoi E. Sychev
ADAbderrahman Day
Abderrahman Day
HBHannah E. Bergom
Hannah E. Bergom
GLGabrianne Larson
Gabrianne Larson
AAAtef Ali
Atef Ali
JDJustin Drake
Justin Drake
Resistance to androgen-deprivation therapies leads to metastatic castration-resistant prostate cancer (mCRPC) of adenocarcinoma (AdCa) origin that can transform into emergent aggressive variant prostate cancer (AVPC), which has neuroendocrine (NE)-like features. In this work, we used LuCaP patient-derived xenograft (PDX) tumors, clinically relevant models that reflect and retain key features of the tumor from advanced prostate cancer patients. Here we performed proteome and phosphoproteome characterization of 48 LuCaP PDX tumors and identified over 94,000 peptides and 9,700 phosphopeptides corresponding to 7,738 proteins. We compared 15 NE versus 33 AdCa samples, which included six different PDX tumors for each group in biological replicates, and identified 309 unique proteins and 476 unique phosphopeptides that were significantly altered and corresponded to proteins that are known to distinguish these two phenotypes. Assessment of concordance from PDX tumor-matched protein and mRNA revealed increased dissonance in transcriptionally regulated proteins in NE and metabolite interconversion enzymes in AdCa. Implications: Overall, our study highlights the importance of protein-based identification when compared with RNA and provides a rich resource of new and feasible targets for clinical assay development and in understanding the underlying biology of these tumors.

2 May 2024
Verified
Other
Open access
ZSZoi E. Sychev
Zoi E. Sychev
ADAbderrahman Day
Abderrahman Day
HBHannah E. Bergom
Hannah E. Bergom
GLGabrianne Larson
Gabrianne Larson
AAAtef Ali
Atef Ali
JDJustin Drake
Justin Drake
Supplementary Table 5. LuCaP Proteome GSEA Pathways

2 May 2024
Verified
Other
Open access
PDF file
ZSZoi E. Sychev
Zoi E. Sychev
ADAbderrahman Day
Abderrahman Day
HBHannah E. Bergom
Hannah E. Bergom
GLGabrianne Larson
Gabrianne Larson
AAAtef Ali
Atef Ali
JDJustin Drake
Justin Drake
Supplementary Figure 1. Sample processing workfow after raw fles were searched using MaxQuant spectra matching to a peptide sequence, for the proteome (green) and for the phosphoproteome (magenta).

2 May 2024
Verified
Other
Open access
ZSZoi E. Sychev
Zoi E. Sychev
ADAbderrahman Day
Abderrahman Day
HBHannah E. Bergom
Hannah E. Bergom
GLGabrianne Larson
Gabrianne Larson
AAAtef Ali
Atef Ali
JDJustin Drake
Justin Drake
Supplementary Table 14. LuCaP AdCa Functional Phosphoproteome

2 May 2024
Verified
Other
Open access
ZSZoi E. Sychev
Zoi E. Sychev
ADAbderrahman Day
Abderrahman Day
HBHannah E. Bergom
Hannah E. Bergom
GLGabrianne Larson
Gabrianne Larson
AAAtef Ali
Atef Ali
JDJustin Drake
Justin Drake
Supplementary Table 4. LuCaP Proteome VSN ROTS NE vs AdCa

2 May 2024
Verified
Other
Open access
ZSZoi E. Sychev
Zoi E. Sychev
ADAbderrahman Day
Abderrahman Day
HBHannah E. Bergom
Hannah E. Bergom
GLGabrianne Larson
Gabrianne Larson
AAAtef Ali
Atef Ali
JDJustin Drake
Justin Drake
Supplementary Table 11. LuCaP Phosphoproteome Kinase Substrate Enrichment Analysis of NE vs AdCa